Ask VialBase
sexual · health

PT-141

Also known as: Bremelanotide, Vyleesi
FDA: FDA-approved as Vyleesi (bremelanotide, 2019) for premenopausal HSDD in women WADA: Not explicitly listed as prohibited
Last updated · 2026-04-12

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist — the first and only FDA-approved on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi since June 2019. Unlike PDE5 inhibitors (Viagra, Cialis) that work on peripheral blood flow, PT-141 acts centrally on the hypothalamus through MC3R and MC4R to modulate sexual desire and arousal at the neurological level. PT-141 was derived from Melanotan II, an analog of alpha-melanocyte-stimulating hormone (α-MSH). During Melanotan II trials, researchers noticed unexpected pro-sexual effects, leading to focused development of bremelanotide as a stand-alone compound for sexual dysfunction. It works in

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 1,025.21 Da
Half-life ~2.7 hours
CAS number —
Route Subcutaneous · Intranasal subcutaneous preferred
Where to buy PT-141 →BioLongevity Labs · save 15% code VIALBASE
02

Dosing

DOSE RANGE 500–2000 mcg
FREQUENCY As needed (45 min before activity, max 1 dose/24 hrs)
CYCLE LENGTH As needed, max 8 doses/month per FDA labeling

Start at 500mcg to assess tolerance. Can cause nausea and flushing. Do not use with tanning peptides (melanotan). Blood pressure may increase transiently.

03

Mechanism

Melanocortin receptor agonist (MC3R/MC4R) — acts on hypothalamic neurons to modulate sexual desire and arousal via CNS pathways, not peripheral vasculature

04

Research summary

Study Type Year Key Finding
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder — RECONNECT Phase III Trials Phase III randomized double-blind placebo-controlled trial 2019 Bremelanotide 1.75mg SC significantly increased sexual desire vs placebo
Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases Review 2025 Mutations in MC1R, MC2R, MC3R and MC4R are associated with melanoma risk, familial glucocorticoid deficiency, obesity and type 2 diabetes, respectively
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer Comprehensive review 2025 Sexual dysfunction is common but underrecognized after breast/gynecologic cancer treatment
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men? Expert review / opinion 2026 Argues bremelanotide should be considered for male sexual arousal and desire disorders
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra phase 1/2 clinical trial 2004 In healthy men given 0.3-10 mg subcutaneously, erectile response was significant at doses above 1.0 mg
Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study randomized controlled trial 2008 Positive clinical results in 51 (33.5%) men on intranasal bremelanotide vs 13 (8.5%) on placebo (p = 0.03)
Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II clinical trial 2000 Melanotan II (parent compound of PT-141) induced erections in men

Stacks containing PT-141

Feminine Vitality & Libido

PT-141 + Oxytocin + Selank (optional)

Libido Lightning

PT-141 (Bremelanotide) + Oxytocin + DSIP

28-day resets featuring PT-141

05

Sourcing

Current prices

Updated today

10mg

Size unspecified

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep

Save 10% with code aewpzbzd at checkout

Stocks this compound Third-party tested Public COAs

Save 50% via this link — discount auto-applied at checkout.

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • Blood Pressure
DURING CYCLE
  • Blood Pressure (30-60 min post-administration)
POST-CYCLE
  • CMP (if frequent use)
Safety & Regulatory Status
FDA STATUS FDA-approved as Vyleesi (bremelanotide, 2019) for premenopausal HSDD in women
WADA STATUS Not explicitly listed as prohibited

Regulatory status for PT-141 may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is PT-141?
PT-141 is a sexual health compound. Melanocortin receptor agonist (MC3R/MC4R) — acts on hypothalamic neurons to modulate sexual desire and arousal via CNS pathways, not peripheral vasculature.
How does PT-141 work?
PT-141 acts through the melanocortin system, a neuroendocrine pathway with broad physiological roles: 1. MC3R/MC4R agonism — PT-141 binds melanocortin receptors 3 and 4 (MC3R and MC4R) in the hypothalamus, particularly in the paraventricular nucleus and medial preoptic area. These regions are central integrators of sexual motivation and arousal (PMID: 41002740).
How is PT-141 dosed?
Commonly cited research protocols use 500–2000 mcg, As needed (45 min before activity, max 1 dose/24 hrs), cycles of As needed, max 8 doses/month per FDA labeling. These figures reflect commonly cited research protocols, not medical advice — consult a clinician.
Is PT-141 FDA-approved?
FDA: Approved — Vyleesi (bremelanotide injection, 1.
What does the research on PT-141 show?
114 PubMed publications as of April 2026. Unique among research peptides in having completed Phase III clinical trials and achieved FDA approval.

References

  1. Kingsberg SA, et al.. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder — RECONNECT Phase III Trials. Obstetrics & Gynecology (2019). PMID: 31599840
  2. Bardhan M, Anand A, Javed A, Chilo MA, Khan N, Garg T, Surana A, Huang H, Samim MM, Suresh V, Khare A, Menon B, Kundu T. Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases. Diseases (2025). PMID: 41002740
  3. Mihulka O, Curran M, Narasimhan RM, Moore JF, Rojas KE. Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer. Journal of Minimally Invasive Gynecology (2025). PMID: 41419078
  4. Pfaus JG, Balon R. Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?. Journal of Clinical Psychopharmacology (2026). PMID: 41960633
  5. Rosen, R.C., Diamond, L.E., Earle, D.C. et al.. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research (2004). PMID: 14999221
  6. Safarinejad, M.R., Hosseini, S.Y.. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of Urology (2008). PMID: 18206919
  7. Wessells, H., Levine, N., Hadley, M.E. et al.. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research (2000). PMID: 11035391